CJC-1295 without DAC

Name: CJC-1295 without DAC
Brand: LyoPep

Tetrasubstituted GRF(1-29) analogue · no DAC · research use only

Lot-specific · Batch COACAS 446036-97-1RUO

Batch COA

MOQ1 kit (10 vials) per SKU

Supplied formLinear 29-residue GHRH/GRF analogue without a DAC albumin-binding group

Lead time7–14 days

CJC-1295 without DAC — Lot-specific lyophilized solid; confirm colour and physical form on the released-batch COA

CJC-1295 without DAC — Lot-specific lyophilized solid; confirm colour and physical form on the released-batch COA · Representative packaging image · verify the ordered lot

Representative packaging image · verify the ordered lot

Decision summary

Key benefits

No sleep, recovery, body-composition, IGF-1, pituitary-support or receptor-desensitisation benefit has been established for this material
Defensible research uses include sequence and identity confirmation, comparison with native GHRH fragments and the DAC construct, controlled GHRHR signalling assays, proteolysis studies, and formulation-specific solubility, adsorption and stability work.

Published research context is presented for literature orientation only. It is not a dosing, treatment or human-use instruction.

Qualification data

Specifications to confirm against the released lot

CAS: 446036-97-1
Formula: C₁₅₂H₂₅₂N₄₄O₄₂
Molecular weight: 3367.9 g/mol
Appearance: Lot-specific lyophilized solid; confirm colour and physical form on the released-batch COA
Purity: Lot-specific released result; request raw chromatography, content assay and orthogonal identity data · target, verify batch COA
Storage: Store and ship according to the batch COA and validated stability data for the exact sequence, counterion, formulation, concentration and container. Generic 2-8 degrees Celsius and two-year statements are not substitutes for real-time or scientifically justified stability evidence. Avoid unvalidated freeze-thaw cycles and record excursions.
MOQ: 1 kit (10 vials) per SKU
Lead time: 7–14 days

PubChem CID 56841945

Qualification matrix

Identity, purity and content are separate release questions.

Identity

Confirm the stated molecule and supplied form. Start with the matching batch COA; request sequence-level evidence only when the buyer's written procedure requires it and availability or a separate scope has been agreed.

Purity

Review RP-HPLC method conditions, wavelength, integration and related-peak handling. A percentage without the method is not enough.

Content

Net peptide content is not the same as gross lyophilized powder weight. Ask which assay supports the stated amount and whether water/counter-ion is addressed.

Stability

Follow the storage condition stated on the batch COA or label from receipt onward.

Research context

What researchers study about CJC-1295 without DAC

CJC-1295 without DAC, often marketed as Modified GRF(1-29) or Mod GRF(1-29), is a 29-residue tetrasubstituted GHRH analogue without the albumin-reactive DAC group. FDA's official 2024 briefing treats CJC-1295 free base and its acetate as a different active moiety from DAC-containing CJC-1295. Naming is inconsistent across supplier catalogues, so the complete sequence, C-terminal amide, counterion and absence of a DAC-bearing Lys30 must be confirmed analytically. The well-known 5.8–8.1-day human half-life and prolonged GH/IGF-1 results belong to the defined DAC-containing investigational molecule, not this no-DAC material. No authoritative dedicated human pharmacokinetic or efficacy study of the no-DAC identity was located; the repeated approximately 30-minute half-life is therefore secondary, not a measured product-specific value.

The no-DAC material is used as a research analogue of modified GHRH(1-29), but no dedicated published human efficacy study was located

Mechanism context

The question the literature is testing

The defined 29-residue analogue is expected to engage GHRHR and activate Gs/cAMP signalling. The commonly reported substitutions are D-Ala2, Gln8, Ala15 and Leu27 relative to the native sequence. These structural differences provide a rationale for laboratory comparison with native GHRH, but the magnitude of receptor affinity, protease resistance, human exposure and GH response must be established by applicable primary data and a qualified test article. A separate GHSR1a mechanism for ipamorelin does not prove synergy or a standard combination ratio.

Evidence map

Research routes and exposure context

Evidence tierApproved finished-product context

Research areaGrowth-hormone axis research

Routes reported in sources

Subcutaneous

Dose / exposure contextProtocol-specific; verify the cited primary source

Routes and exposure contexts summarize cited studies or approved finished-product labels. They are not instructions for administering this RUO material; no customer dose is provided.

Evidence boundaries

Compatibility, limitations and decision context

The no-DAC peptide is not an approved medicine and lacks a dedicated human safety database
FDA's official 2024 briefing identified inconsistent identity, peptide-related impurities, aggregation, immunogenicity, nonclinical toxicity and limited clinical evidence as material concerns across CJC-1295-related forms
Final PCAC minutes record 0 yes to 13 no for CJC-1295 free base and 1 yes to 12 no for CJC-1295 acetate on Section 503A Bulks List inclusion; committee advice is non-binding
FDA's current significant-safety-risk page states that compounded CJC-1295 may pose immunogenicity and characterization risks, available clinical data are limited, and serious adverse events including increased heart rate and systemic vasodilatory reaction have been identified
CJC-1295 is prohibited at all times under WADA 2026 S2.2.4
This material is not for human or veterinary use; laboratory work should follow institutional review and batch safety documentation.

Interactions reported in the literature

No product-specific human interaction protocol exists
Mechanistic expectations about GHRH-receptor signaling do not validate combinations with GHRPs, GH, insulin or other secretagogues
Community synergy and stack labels were removed because no controlled no-DAC interaction study supports them.

Literature context is not a supplier release result or human-use instruction. Follow your institution's approved laboratory risk assessment.

Batch documentation

CJC-1295 without DAC batch COAs

Laboratory: Manufacturer's QC laboratoryTests: HPLC purity · MS identity · endotoxin · fill amount

2 mg
5 mg
10 mg

Previews are blurred on purpose so the documents cannot be reused; third-party reports show their first page only. Sales sends the clear full version for the product and strength you ask about.

Independent test fails? Full refund.

Representative records, refreshed periodically

Published COAs show recent representative batches and may not be the newest. For a quote or shipment, sales confirms the lot and sends its COA.

Third-party reports, added progressively

Previews of the first page of third-party reports are on our Quality page and on the matching product pages; sales sends the full report on request. You can also send any vial from your order to an independent laboratory of your choice. Unless agreed otherwise in writing, the buyer pays for optional testing.

Help reviewing your COA

Need help reading a batch COA or third-party report? Sales can explain the test items, specifications and how the results relate to the lot under discussion.

On every batch COA: HPLC purity · MS identity · endotoxin · fill amount · Verify LyoPep

Ask for the current packet, not a generic certificate

A supplier must distinguish the 29-residue no-DAC peptide from albumin-reactive DAC-containing CJC-1295
Qualification should require the complete sequence and terminal state, counterion, high-resolution intact mass and sequence-confirming MS/MS, chromatographic purity with raw chromatograms and impurity profile, quantitative peptide content, residual solvents, water and counterion content, and lot-specific stability
A vacuum-sealed vial, white powder, CAS label or nominal HPLC percentage does not prove the absence of a DAC linker or confirm identity
Sterility and endotoxin require separate validated tests.

Batch COA for the released lotHPLC purity with method contextMS identity resultEndotoxin resultFill amount (measured content per vial)SDS and handling statement

Available fills

Quote the fill and pack configuration you need

Reference SKUFillBase pack

CJC22 mg10 vials

CJC55 mg10 vials

CJC1010 mg10 vials

Other format

Also available as a nasal spray (US stock)

Black 10 mL nasal spray bottle with a clear cap — 10 mL nasal spray bottle

Besides lyophilized vials, CJC-1295 without DAC is also supplied as a nasal spray solution, shipped from our US stock.

Strengths: 2 mg · 5 mg
Bottle sizes: 10 mL or 20 mL
Minimum order: 10 bottles per strength and bottle size
Ships from: Our US stock

Handling

Plan storage before the parcel arrives

Store and ship according to the batch COA and validated stability data for the exact sequence, counterion, formulation, concentration and container. Generic 2-8 degrees Celsius and two-year statements are not substitutes for real-time or scientifically justified stability evidence. Avoid unvalidated freeze-thaw cycles and record excursions.

State the destination and timing so receipt can be planned, then move the material into its stated storage condition on arrival.

Buyer FAQ

Terms to settle before the purchase order

Can a buyer arrange third-party testing?+

Yes. You can send any vial from your order to an independent laboratory of your choice. If you want the laboratory, specification, sampling, method and acceptance rule agreed with us before testing, sales confirms them in writing. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

What if my own lab test shows the product is out of specification?+

Send any vial from your order to an independent laboratory of your choice. If the report shows the product does not meet the specification on its COA — purity below the stated minimum, or an identity that does not match — share the report with our sales team and we refund that product in full.

Does HPLC purity prove peptide content?+

No. Chromatographic purity describes the relative peak profile under a stated method. Identity, water, counter-ion, residual solvents and assay/content may require separate methods.

How should material be stored after delivery?+

Move it into the storage condition stated on the batch COA or label as soon as it arrives, and record the package condition on receipt.

How are payment terms handled?+

Available methods and milestones depend on order value, destination and project type. The pro forma invoice should state currency, bank details, fees, payment milestones and the release condition.

Why must the testing laboratory understand peptide chemistry?+

Free-base and salt forms, hydrophilic and hydrophobic sequences, aggregation and adsorption can change sample preparation and method suitability. Use a laboratory experienced with the molecule class.

External qualification references

WHO good storage and distribution practices ISO/IEC 17025 laboratory competence 21 CFR 211.84 component testing and supplier COA controls

These are buyer-qualification references, not claims that this RUO material is regulated, certified or released under those frameworks. Applicability depends on the buyer's workflow and jurisdiction.

Selected sources

Literature behind the research context

The principal CJC-1295 papers by Jetté et al. (Endocrinology 2005, DOI 10.1210/en.2004-1286), Teichman et al. (JCEM 2006, DOI 10.1210/jc.2005-1536) and Ionescu and Frohman (JCEM 2006, DOI 10.1210/jc.2006-1702) concern the DAC-containing long-acting molecule and are retained to prevent extrapolation. They do not establish no-DAC human pharmacokinetics, efficacy or dosing. PubChem CID 91976842 and FDA's 2024 briefing support the 29-residue free-peptide identity, formula C₁₅₂H₂₅₂N₄₄O₄₂ and mass near 3,367.9 Da. FDA's final PCAC minutes record form-specific advisory votes, while its current significant-safety-risk page provides ongoing agency risk context. WADA's official 2026 Prohibited List supplies the current anti-doping classification. None of these sources qualifies a supplied lot or creates an approved use.

01
Human Growth Hormone-Releasing Factor (hGRF)1-29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long-Lasting GRF Analog
Endocrinology · 2005 · peer-reviewed original research
Open source
02
Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults
The Journal of Clinical Endocrinology & Metabolism · 2006 · peer-reviewed original research (clinical trial)
Open source
03
Pulsatile Secretion of Growth Hormone (GH) Persists during Continuous Stimulation by CJC-1295, a Long-Acting GH-Releasing Hormone Analog
The Journal of Clinical Endocrinology & Metabolism · 2006 · peer-reviewed original research (clinical trial)
Open source
04
FDA Briefing Document: CJC-1295-Related Bulk Drug Substances
U.S. Food and Drug Administration · 2024 · official regulatory briefing
Open source
05
Final Minutes: December 4, 2024 Pharmacy Compounding Advisory Committee Meeting
U.S. Food and Drug Administration · 2024 · official advisory committee minutes
Open source
06
PubChem Compound Summary: CJC1295 Without DAC (CID 91976842)
PubChem · 2026 · authoritative public chemical database
Open source
07
Certain Bulk Drug Substances for Use in Compounding May Present Significant Safety Risks
U.S. Food and Drug Administration · 2026 · current official regulatory safety resource
Open source
08
2026 Prohibited List
World Anti-Doping Agency · 2026 · official anti-doping authority list
Open source

Product FAQ

Questions buyers ask about CJC-1295 without DAC

What is the evidence-based difference between with-DAC and no-DAC CJC-1295?+

The no-DAC material is a 29-residue modified GRF(1-29) analogue. The with-DAC material adds a C-terminal Lys30 bearing a reactive maleimidopropionyl group and therefore has a different mass, identity and analytical specification. Human 5.8–8.1-day pharmacokinetic data belong to the defined DAC-containing investigational molecule. No authoritative dedicated human pharmacokinetic study was located for the no-DAC identity, so the widely repeated approximately 30-minute value must not be presented as a measured product-specific fact.

Evidence before order

Buyer intelligence

Ready for review

Request a usable quote

Include fill, quantity, target purity/content, required methods, destination and timing.

B2B response target: 24 hours
1 kit MOQ per SKU
Batch COA: HPLC, MS, endotoxin, fill

Research Use Only. Human-use requests are not accepted.

Recent activity window

Recent confirmed orders including CJC-1295 without DAC

Recent Confirmed Orders8 · Last 30 days

United States300 mg2026-11-11

CJC-1295 without DAC 10 mg · Survodutide 10 mg

United States2.3 g2026-11-10

Tirzepatide 100 mg · Melanotan II 10 mg · GHK-Cu 50 mg · TB-500 10 mg · CJC-1295 without DAC 10 mg

United States6.9 g2026-11-04

Tirzepatide 100 mg · CJC-1295 without DAC 10 mg · TB-500 10 mg · CJC-1295 + Ipamorelin 10 mg · Semaglutide 30 mg · IGF-1 LR3 1000 mcg · Sterile Water 3 mL

United Kingdom26 g2026-10-23

Tirzepatide 120 mg · PE-22-28 10 mg · BPC-157 + TB-500 (Wolverine Stack) 30 mg · Semaglutide 50 mg · MOTS-c (Human) 40 mg · CJC-1295 without DAC 10 mg

Australia23 g2026-10-22

Retatrutide 60 mg · Sermorelin 10 mg · Hexarelin Acetate 5 mg · Semaglutide 50 mg · Tesa+IP5 15 mg · BPC-157 10 mg · Melanotan II 10 mg · Kisspeptin-10 10 mg · TB500 Fragment (Frag 17-23) 10 mg · CJC-1295 without DAC 10 mg · MOTS-c (Human) 40 mg

Singapore6.8 g2026-10-21

Tirzepatide 90 mg · BPC-157 10 mg · TB-500 10 mg · CJC-1295 without DAC 10 mg

United Kingdom100 mg2026-10-15

Tirzepatide 2 mg · CJC-1295 without DAC 2 mg

Australia105.1 g2026-10-13

Glutathione 1500 mg · Selank 11 mg · Tirzepatide 120 mg · CagriSema 20 mg · Pinealon 10 mg · BPC-157 10 mg · KLOW (GHK-Cu + BPC-157 + TB-500 + KPV) 80 mg · Melanotan II 10 mg · CJC-1295 without DAC 10 mg · Thymosin Alpha 1 10 mg · TB-500 10 mg · CJC-1295 + Ipamorelin 10 mg · Bacteriostatic Water 3 ml

Only a portion of all confirmed orders is shown here.

CJC-1295 without DAC

Key benefits

Specifications to confirm against the released lot

Identity, purity and content are separate release questions.

What researchers study about CJC-1295 without DAC

The question the literature is testing

Research routes and exposure context

Compatibility, limitations and decision context

Interactions reported in the literature

CJC-1295 without DAC batch COAs

Ask for the current packet, not a generic certificate

Quote the fill and pack configuration you need

Also available as a nasal spray (US stock)

Plan storage before the parcel arrives

Terms to settle before the purchase order

Literature behind the research context

Human Growth Hormone-Releasing Factor (hGRF)1-29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long-Lasting GRF Analog

Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults

Pulsatile Secretion of Growth Hormone (GH) Persists during Continuous Stimulation by CJC-1295, a Long-Acting GH-Releasing Hormone Analog

FDA Briefing Document: CJC-1295-Related Bulk Drug Substances

Final Minutes: December 4, 2024 Pharmacy Compounding Advisory Committee Meeting

PubChem Compound Summary: CJC1295 Without DAC (CID 91976842)

Certain Bulk Drug Substances for Use in Compounding May Present Significant Safety Risks

2026 Prohibited List

Questions buyers ask about CJC-1295 without DAC

Buyer intelligence

Compare adjacent molecules and documentation needs.

Ipamorelin

CJC 5mg + IPA 5mg

Sermorelin

CJC-1295 with DAC